Skip to main content
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
Easy-to-follow guides
Independent reviews
Vetted providers
Free to read

Home / Peptide legality / Alaska

Peptide legality · Alaska · updated 2026-09-21

Are peptides legal in Alaska?

Gray area

Alaska sits in a gray zone, because the state has no peptide specific statute or Board of Pharmacy rule and instead governs peptides through general drug and pharmacy law layered on top of federal FDA compounding rules.

Legal status overview

Alaska is a gray zone state: it has no statute, administrative regulation, or Board of Pharmacy rule that treats peptides or research chemicals as a distinct legal category. Peptides are handled through general prescription drug requirements, the Board of Pharmacy compounding and licensing rules in AS 08.80 and 12 AAC 52, and federal FDA law on approved drugs and 503A/503B compounding. FDA approved prescription peptide medicines such as Wegovy® (semaglutide) and somatropin remain legal when prescribed and dispensed properly. Selling or administering unapproved peptides can still implicate state pharmacy, misbranding, and professional licensing law, and any compounded medication is not FDA-approved; not a generic; not evaluated by the FDA.

Key points

  • Alaska has no statute, administrative regulation, or Board of Pharmacy rule that names peptides or research chemicals as a distinct legal category. [2]
  • Peptides in Alaska are governed by general prescription drug and pharmacy law under AS 08.80 and 12 AAC 52, plus the Board of Pharmacy compounding and licensing rules. [1]
  • FDA approved prescription peptide drugs remain legal when prescribed and dispensed properly, including Wegovy® (semaglutide) and somatropin. [5]
  • Compounding of semaglutide is no longer permitted now that the FDA has declared the shortage resolved, and compounded semaglutide is not FDA-approved; not a generic; not evaluated by the FDA. [5]
  • The FDA identifies BPC-157 as a bulk drug substance that may present significant safety risks in compounding, and later removed it from the Category 2 restricted list without moving it to the permitted Category 1 list, leaving it in regulatory limbo. [6]
  • Under Section 503A, only substances with an approved application, a USP or NF monograph, or a place on the FDA bulks list may be compounded, which excludes peptides such as BPC-157 and TB-500. [4]
  • Non prescription distribution of human growth hormone, including somatropin, is a federal felony under 21 U.S. Code section 333(e). [7]
  • The FDA has flagged BPC-157 for immunogenicity and peptide impurity concerns as part of its safety review. [3]

Compound-by-compound status

BPC-157
Gray area
Not FDA-approved; not a generic; not evaluated by the FDA. Removed from the Category 2 restricted list in 2026 but not moved to permitted Category 1, so it remains in regulatory limbo and is not authorized for routine 503A compounding.
GLP-1 class (semaglutide, tirzepatide)
Legal
FDA approved brands such as Wegovy® (semaglutide) and Zepbound® (tirzepatide) are legal by valid prescription. Compounded semaglutide is no longer permitted now the shortage is resolved and is not FDA-approved; not a generic; not evaluated by the FDA.
TB-500 (thymosin beta 4)
Restricted
Not FDA-approved; not a generic; not evaluated by the FDA. It lacks a USP or NF monograph and is not on the permitted 503A bulks list, so it is not authorized for compounding.
Growth hormone / somatropin
Legal
FDA approved prescription drug, legal for recognized indications when prescribed. Non prescription distribution is a federal felony under 21 U.S. Code section 333(e).

Frequently asked questions

Are peptides specifically illegal in Alaska?

No specific state peptide ban exists. Alaska applies general prescription drug and pharmacy law under AS 08.80 and 12 AAC 52 together with federal FDA compounding rules, which is why the category sits in a gray zone.

Can a compounding pharmacy in Alaska make BPC-157?

BPC-157 is not FDA-approved and is not on the permitted 503A bulks list, so it is not authorized for routine compounding even though it was removed from the Category 2 restricted list. This is information, not legal advice.

Is Wegovy® (semaglutide) legal in Alaska?

Yes. FDA approved brand GLP-1 medicines are legal when prescribed and dispensed lawfully. Compounded semaglutide is no longer permitted because the FDA shortage has ended.

Is human growth hormone legal in Alaska?

Somatropin is an FDA approved prescription drug and is legal for recognized indications when prescribed. Non prescription distribution is a federal felony under 21 U.S. Code section 333(e).

Does a gray zone mean peptides are automatically allowed?

No. A gray zone means there is no peptide specific state law, but general pharmacy, misbranding, and federal drug law still apply, so unapproved products can still be unlawful.

Sources

  1. Statutes and Regulations, Alaska Board of Pharmacy, April 2025 (AS 08.80 and 12 AAC 52) (retrieved 2026-09-21)
  2. Statutes and Regulations, Board of Pharmacy, Alaska Division of Corporations, Business and Professional Licensing (retrieved 2026-09-21)
  3. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA (retrieved 2026-09-21)
  4. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA (retrieved 2026-09-21)
  5. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize, FDA (retrieved 2026-09-21)
  6. FDA Removes Certain Peptide Bulk Drug Substances from Category 2 of Interim 503A Bulks List, Lexology (retrieved 2026-09-21)
  7. 21 U.S. Code section 333, Penalties, Legal Information Institute (retrieved 2026-09-21)

Last researched: 2026-09-21.

General information based on the sourced research above, not legal advice. For a specific situation in Alaska, consult a licensed attorney familiar with pharmaceutical law.